Fingerprint
Dive into the research topics of 'Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
Ruben A. Mesa
Research output: Contribution to journal › Article › peer-review
6
Scopus
citations